S
Sheng Xiao
Researcher at Brigham and Women's Hospital
Publications - 127
Citations - 14018
Sheng Xiao is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: T cell & Cellular differentiation. The author has an hindex of 46, co-authored 118 publications receiving 12255 citations. Previous affiliations of Sheng Xiao include Boston University & Harvard University.
Papers
More filters
Journal ArticleDOI
Induction and molecular signature of pathogenic TH17 cells
Youjin Lee,Amit Awasthi,Amit Awasthi,Nir Yosef,Nir Yosef,Francisco J. Quintana,Sheng Xiao,Anneli Peters,Chuan Wu,Markus Kleinewietfeld,Sharon R. Kunder,David A. Hafler,Raymond A. Sobel,Aviv Regev,Aviv Regev,Vijay K. Kuchroo +15 more
TL;DR: It is found that the production of TGF-β3 by developing Th17 cells was dependent on IL-23, which together with IL-6 induced very pathogenic TH17 cells, which had a molecular signature that defined pathogenic effector TH 17 cells in autoimmune disease.
Journal Article
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Brian P. Rubin,Samuel Singer,Connie W. Tsao,Anette Duensing,Marcia L. Lux,Robert Ruiz,Michele K. Hibbard,Chang-Jie Chen,Sheng Xiao,David A. Tuveson,George D. Demetri,Christopher D.M. Fletcher,Jonathan A. Fletcher +12 more
TL;DR: It is suggested that activated KIT might represent a universal therapeutic target in GISTs, and mutations in all KIT domains were associated with high-level KIT activation/phosphorylation, and KITactivation was also demonstrated in the four Gists that lacked detectable KIT genomic and cDNA mutations.
Journal ArticleDOI
Induction of pathogenic Th17 cells by inducible salt sensing kinase SGK1
Chuan Wu,Nir Yosef,Nir Yosef,Theresa Thalhamer,Theresa Thalhamer,Chen Zhu,Sheng Xiao,Yasuhiro Kishi,Aviv Regev,Aviv Regev,Vijay K. Kuchroo,Vijay K. Kuchroo +11 more
TL;DR: It is shown that a modest increase in salt concentration induces SGK1 expression, promotes IL-23R expression and enhances TH17 cell differentiation in vitro and in vivo, accelerating the development of autoimmunity.
Journal ArticleDOI
TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
Brandon D. Lawrence,Antonio R. Perez-Atayde,Michele K. Hibbard,Brian P. Rubin,Paola Dal Cin,Jack L. Pinkus,Geraldine S. Pinkus,Sheng Xiao,Eunhee S. Yi,Christopher D.M. Fletcher,Jonathan A. Fletcher,Jonathan A. Fletcher +11 more
TL;DR: A recurrent oncogenic mechanism is reported, in IMTs, in which tropomyosin N-terminal coiled-coil domains are fused to the ALK C- terminal kinase domain, the first known fusion oncogene that transforms, in vivo, both mesenchymal and lymphoid human cell lineages.
Journal ArticleDOI
Dynamic regulatory network controlling Th17 cell differentiation
Nir Yosef,Alex K. Shalek,Jellert T. Gaublomme,Hulin Jin,Youjin Lee,Amit Awasthi,Amit Awasthi,Chuan Wu,Katarzyna Karwacz,Sheng Xiao,Marsela Jorgolli,David Gennert,Rahul Satija,Arvind Shakya,Diana Lu,John J. Trombetta,Meenu R. Pillai,Peter J. Ratcliffe,Mathew L. Coleman,Mark Bix,Dean Tantin,Hongkun Park,Hongkun Park,Vijay K. Kuchroo,Vijay K. Kuchroo,Aviv Regev,Aviv Regev +26 more
TL;DR: This study identifies and validates 39 regulatory factors, embeds them within a comprehensive temporal network and reveals its organizational principles; it also highlights novel drug targets for controlling TH17 cell differentiation.